Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 25,005
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12584120 | PCSK9 inhibitors and methods of use thereof | 🖼🧊📄§ | 2026-03-24 | 2043-01-25 | 0 | 31 |
| 12582662 | Injectable pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent and a preservative | 🖼🧊📄§ | 2026-03-24 | 2043-05-26 | 0 | 31 |
| 12584116 | Attenuated variant of the rift valley fever virus, composition comprising same, and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2041-06-03 | 0 | 31 |
| 12583884 | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | 🖼🧊📄§ | 2026-03-24 | 2039-12-18 | 0 | 31 |
| 12582640 | Treatment of lower respiratory tract infection with tradipitant | 🖼🧊📄§ | 2026-03-24 | 2041-03-24 | 0 | 31 |
| 12584146 | Synthetic modified vaccinia Ankara (SMVA) based coronavirus vaccines | 🖼🧊📄§ | 2026-03-24 | 2045-04-18 | 0 | 31 |
| 12583905 | Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells | 🖼🧊📄§ | 2026-03-24 | 2044-11-20 | 0 | 31 |
| 12584138 | Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies | 🖼🧊📄§ | 2026-03-24 | 2041-08-26 | 0 | 31 |
| 12582725 | AAV vectors with myelin protein zero promoter and uses thereof for treating SCHWANN cell-associated diseases like CHARCOT-MARIE-TOOTH disease | 🖼🧊📄§ | 2026-03-24 | 2040-06-03 | 0 | 31 |
| 12584149 | Nuclease-mediated genome editing of primary cells and related kits | 🖼🧊📄§ | 2026-03-24 | 2042-12-05 | 0 | 31 |
| 12582682 | Probiotic compositions for the treatment of acne | 🖼🧊📄§ | 2026-03-24 | 2041-09-14 | 0 | 31 |
| 12582638 | Pharmaceutical composition for treating cancer, containing mTOR-signaling inhibitor as active ingredient | 🖼🧊📄§ | 2026-03-24 | 2041-02-19 | 0 | 31 |
| 12582689 | Use of terpenoids in the treatment or prevention of fibrotic diseases | 🖼🧊📄§ | 2026-03-24 | 2041-05-19 | 0 | 31 |
| 12582705 | Composition comprising botulinum toxin or salt thereof for increasing endometrial blood flow rate | 🖼🧊📄§ | 2026-03-24 | 2040-04-28 | 0 | 31 |
| 12582723 | Polynucleotides encoding a human FKRP protein | 🖼🧊📄§ | 2026-03-24 | 2043-03-02 | 0 | 31 |
| 12582668 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | 🖼🧊📄§ | 2026-03-24 | 2040-06-05 | 0 | 31 |
| 12582691 | Administration of Yunnan Baiyao or Xingnaojing in patients with moderate-to-severe traumatic brain injury and craniotomy | 🖼🧊📄§ | 2026-03-24 | 2042-07-12 | 0 | 31 |
| 12583888 | Bi-specific extracellular matrix binding peptides and methods of use thereof | 🖼🧊📄§ | 2026-03-24 | 2040-02-03 | 0 | 31 |
| 12583852 | Heterocycle derivative | 🖼🧊📄§ | 2026-03-24 | 2039-05-02 | 0 | 31 |
| 12582624 | Co-crystal of gabapentin, ketoprofen and lysine, pharmaceutical compositions and their medical use | 🖼🧊📄§ | 2026-03-24 | 2041-04-21 | 0 | 31 |
| 12577249 | GCN2 and perk kinase inhibitors and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2042-12-02 | 0 | 31 |
| 12576138 | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase | 🖼🧊📄§ | 2026-03-17 | 2039-05-17 | 0 | 31 |
| 12576100 | Nucleic acid agents modulating SLAMF6 isoforms | 🖼🧊📄§ | 2026-03-17 | 2040-06-23 | 0 | 31 |
| 12577238 | Compositions and methods for modulating inflammatory and degenerative disorder | 🖼🧊📄§ | 2026-03-17 | 2042-08-17 | 0 | 31 |
| 12577304 | Anti-CD3 antibodies with low binding affinity | 🖼🧊📄§ | 2026-03-17 | 2041-03-19 | 0 | 31 |
| 12576121 | Acacia nilotica based hydrogel and method of making the same | 🖼🧊📄§ | 2026-03-17 | 2045-12-12 | 0 | 31 |
| 12576070 | Medicine for improving state of pregnancy, and use thereof | 🖼🧊📄§ | 2026-03-17 | 2042-11-23 | 0 | 31 |
| 12576063 | Implantable drug delivery devices for localized drug delivery | 🖼🧊📄§ | 2026-03-17 | 2040-12-18 | 0 | 31 |
| 12577287 | T cell receptors and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2040-03-24 | 0 | 31 |
| 12577247 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | 🖼🧊📄§ | 2026-03-17 | 2042-01-07 | 0 | 31 |
| 12576140 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases | 🖼🧊📄§ | 2026-03-17 | 2041-07-29 | 0 | 31 |
| 12576137 | Collagen hydrolysate comprising GPCR ligand peptide | 🖼🧊📄§ | 2026-03-17 | 2042-11-23 | 0 | 31 |
| 12577310 | Caninized antibodies to canine interleukin-31 receptor alpha | 🖼🧊📄§ | 2026-03-17 | 2041-10-14 | 0 | 31 |
| 12577222 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2044-01-19 | 0 | 31 |
| 12577201 | Glutamine analogs | 🖼🧊📄§ | 2026-03-17 | 2041-10-14 | 0 | 31 |
| 12577320 | Anti-Claudin 18.2 antibody and antibody-drug conjugate thereof | 🖼🧊📄§ | 2026-03-17 | 2042-05-07 | 0 | 31 |
| 12576055 | Disease detection and treatment based on trimethyl-lysine levels | 🖼🧊📄§ | 2026-03-17 | 2039-02-01 | 0 | 31 |
| 12576040 | Ionizable lipids and methods of manufacture and use thereof | 🖼🧊📄§ | 2026-03-17 | 2041-10-13 | 0 | 31 |
| 12576052 | Metformin inhalation powder aerosol for treating idiopathic pulmonary fibrosis and preparation method thereof | 🖼🧊📄§ | 2026-03-17 | 2043-07-28 | 0 | 31 |
| 12576079 | Methods for treating cholestasis | 🖼🧊📄§ | 2026-03-17 | 2040-12-11 | 0 | 31 |
| 12576128 | Genetically engineered microorganisms and methods of use | 🖼🧊📄§ | 2026-03-17 | 2040-05-01 | 0 | 31 |
| 12576024 | Compositions comprising Propionibacterium acnes bacteriophages for treating acne | 🖼🧊📄§ | 2026-03-17 | 2044-01-16 | 0 | 31 |
| 12577208 | TEAD inhibitors and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2043-06-16 | 0 | 31 |
| 12576118 | Bacteriophages for the treatment of tuberculosis | 🖼🧊📄§ | 2026-03-17 | 2040-05-21 | 0 | 31 |
| 12576053 | Use of 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl) methylidenejinden-1-yl] acetic acid | 🖼🧊📄§ | 2026-03-17 | 2038-04-11 | 0 | 31 |
| 12576051 | Methods and composition for treating respiratory obstructive diseases | 🖼🧊📄§ | 2026-03-17 | 2040-07-30 | 0 | 31 |
| 12576101 | Application based nucleotides of Lactobacillus rhamnosus to prepare a composition for anti-lipogenesis | 🖼🧊📄§ | 2026-03-17 | 2044-05-29 | 0 | 31 |
| 12577290 | FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death | 🖼🧊📄§ | 2026-03-17 | 2042-03-04 | 0 | 31 |
| 12576083 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | 🖼🧊📄§ | 2026-03-17 | 2044-01-17 | 0 | 31 |
| 12577318 | Humanized anti-CA IX antibodies and methods of their use | 🖼🧊📄§ | 2026-03-17 | 2039-11-05 | 0 | 31 |